梯瓦製藥 TEVA 深滬

已收盤 01-09 16:00:00 美东时间

32.01

-0.500

-1.54%

華盛通

立即下載

最高32.73
今開32.49
成交量 957.36万股
最低 31.795
昨收 32.51
總市值 367.15亿
52周最高 32.91
市盈率 ^靜 --
換手率 0.83%
52周最低 12.465
委比 28.32%
總股本 11.47亿
歷史最高 69.8535
量比 0.76
振幅 2.88%
歷史最低 6.07
每手 1
風險率 4.62%

個股概要

財務分析

公司資料

分紅派息

分時圖
日k
周k
月k

相關新聞

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Teva and Royalty Pharma have signed a $500 million agreement to support the development of Teva's anti-IL-15 antibody, TEV-‘408, targeting vitiligo and celiac disease. TEV-‘408 is in Phase 1b for vitiligo and Phase 2a for celiac disease. The deal includes $75 million for Phase 2b funding and an option for $425 million for Phase 3. The collaboration aims to accelerate innovative treatments for patients with autoimmune conditions.

01-11 22:00
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference

Teva Pharmaceutical Industries Ltd. announced that its CEO, Richard Francis, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The presentation will start at 8:15 A.M. Pacific Time and can be accessed via Teva’s Investor Relations website. A recording will be available within 24 hours and accessible for 30 days. Teva, a leading biopharmaceutical company, focuses on innovative medicines and generics, aiming to ...

01-05 21:30
Top 2 Health Care Stocks That May Crash In Q1

As of Jan. 2, 2026, two stocks in the health care sector could be flashing a re...

01-02 21:58
Teva Pharmaceutical Stock Hits 52-Week High On Credit Ratings Lift

S&P upgraded Teva to BB+ and Moody's turned positive, citing falling leverage, stronger cash flow, and branded drug momentum that could support a future investment-grade rating.

2025-12-24 22:51
Sanofi, Regeneron’s Dupixent approved in Japan for children with asthma

Sanofi (SNY) and Regeneron’s (REGN) asthma treatment, Dupixent, has been approved in Japan for children aged 6 to 11, marking a significant expansion of the drug’s pediatric use. This expands the prev...

2025-12-23 18:35
美股大行评级 | 潜在涨幅498.16%！SurgePays Inc获Ascendiant Capital升目标价至9.75美元，维持"买入"评级

今日重点评级关注：Ascendiant Capital：维持SurgePays Inc"买入"评级，目标价从9.5美元升至9.75美元；Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从8美元升至10美元

2025-12-23 12:32
Alvotech announces European launch of biosimilar to Simponi

Alvotech (ALVO) said on Monday that launches are underway in Europe for Gobivaz (golimumab), Alvotech’s biosimilar to Simponi (golimumab), also known as AVT05. Gobivaz is the first marketed biosimil...

2025-12-22 15:21
美股大行评级 | 绩后评级出炉！联邦快递获多家大行上调目标价；耐克遭多家大行下调目标价

今日重点评级关注：HC Wainwright & Co.：维持Pyxis Oncology"买入"评级，目标价从5美元升至7美元；Stifel：维持Oculis Holding"买入"评级，目标价从35美元升至40美元

2025-12-22 15:05
Oklo, AppLovin, Teva, Fastly, Intuit: Insider Sell-Offs

Insiders have been trading these 5 stocks: (($OKLO)), (($APP)), (($TEVA)), (($F...

2025-12-20 21:01
Goldman Sachs Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $35

Goldman Sachs analyst Matt Dellatorre maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $31 to $35.

2025-12-20 01:08

派息除權日	每股總股息	派息日期
2017-11-27	0.07	2017-12-12
2017-08-25	0.07	2017-09-14
2017-06-01	0.29	2017-06-22
2017-02-28	0.29	2017-03-20
2016-12-01	0.29	2016-12-20
2016-08-18	0.29	2016-09-08
2016-05-20	0.29	2016-06-07
2016-02-25	0.29	2016-03-14
2015-11-13	0.29	2015-12-03
2015-08-18	0.29	2015-09-03
2015-05-15	0.29	2015-06-04
2015-02-17	0.29	2015-03-03
2014-11-13	0.27	2014-12-02
2014-08-19	0.29	2014-09-04
2014-05-16	0.30	2014-06-02
2014-02-20	0.29	2014-03-10
2013-11-18	0.28	2013-12-03
2013-08-16	0.27	2013-09-03
2013-05-16	0.27	2013-06-03
2013-02-19	0.27	2013-03-07
2012-11-13	0.20	2012-12-03
2012-08-13	0.21	2012-09-04
2012-05-17	0.20	2012-06-04
2012-02-23	0.20	2012-03-15
2011-11-09	0.17	2011-12-07
2011-08-04	0.20	2011-08-25
2011-05-19	0.20	2011-06-07
2011-02-10	0.22	2011-03-07
2010-11-08	0.17	2010-12-06
2010-08-02	0.17	2010-08-26
2010-05-10	0.16	2010-06-04
2010-02-19	0.16	2010-03-17
2009-11-06	0.13	2009-12-04
2009-08-03	0.12	2009-08-27
2009-05-08	0.12	2009-06-03
2009-02-23	0.11	2009-03-19
2008-11-07	0.09	2008-12-05
2008-08-01	0.10	2008-08-27
2008-05-13	0.11	2008-06-05
2008-02-15	0.10	2008-03-13
2007-11-02	0.08	2007-11-28
2007-08-10	0.08	2007-09-06
2007-05-10	0.08	2007-06-05
2007-02-16	0.08	2007-03-15
2006-11-10	0.07	2006-12-06
2006-08-11	0.06	2006-09-08
2006-05-12	0.06	2006-06-07
2006-03-06	0.06	2006-03-30
2005-11-10	0.05	2005-12-07
2005-08-11	0.05	2005-09-07
2005-05-05	0.06	2005-06-01
2005-02-17	0.06	2005-03-17
2004-11-09	0.04	2004-12-06
2004-08-09	0.04	2004-09-07
2004-05-10	0.15	2004-06-07
2004-02-20	0.08	2004-03-22
2003-11-13	0.06	2003-12-12
2003-08-08	0.06	2003-09-08
2003-05-08	0.06	2003-06-06
2003-02-24	0.05	2003-03-24
2002-11-07	0.07	2002-12-06
2002-08-19	0.07	2002-09-16
2002-05-20	0.07	2002-06-17
2002-02-15	0.08	2002-03-18
2001-11-16	0.05	2001-12-17
2001-08-20	0.05	2001-09-17
2001-05-17	0.05	2001-06-15
2001-03-08	0.05	2001-04-06
2000-11-16	0.04	2000-12-15
2000-08-24	0.04	2000-09-21
2000-05-19	0.04	2000-06-19
2000-02-17	0.08	2000-03-27
1999-11-04	0.05	1999-11-30
1999-08-18	0.05	1999-09-13
1999-05-21	0.05	1999-06-15
1999-03-08	0.05	1999-03-30
1998-11-20	0.05	1998-12-11
1998-08-21	0.06	1998-09-11
1998-05-21	0.06	1998-06-22
1998-03-12	0.06	1998-03-31
1997-11-20	0.07	1997-12-09
1997-08-25	0.07	1997-09-11
1997-05-23	0.07	1997-06-12
1997-03-07	0.07	1997-03-26
1996-11-20	0.05	1996-12-09
1996-08-26	0.05	1996-09-12
1996-05-23	0.05	1996-06-12
1996-03-07	0.05	1996-03-26
1995-11-20	0.05	1995-12-07
1995-08-14	0.05	1995-08-30
1995-05-17	0.05	1995-06-07
1995-03-07	0.05	1995-04-04
1994-11-15	0.05	1994-12-13
1994-08-09	0.05	1994-09-12
1994-05-18	0.05	1994-06-21
1994-03-08	0.05	1994-04-05
1993-11-17	0.04	1994-01-03
1993-08-17	0.04	1993-09-14
1993-05-18	0.03	1993-06-21
1993-04-07	0.06	1993-05-05
1992-11-17	0.04	1992-12-21
1992-08-18	0.04	1992-09-21
1991-11-20	0.04	1991-12-19
1991-08-21	0.04	1991-09-19
1991-05-20	0.04	1991-07-20
1991-03-05	0.04	1991-03-28
1990-11-20	0.04	1990-12-20
1990-08-17	0.04	1990-09-17
1989-05-22	0.04	1989-06-19
1988-12-06	0.04	1988-12-30
1988-09-08	0.04	1988-10-05
1988-06-10	0.03	1988-07-20
1988-04-11	0.03	1988-05-16
1988-02-08	0.03	1988-03-10
1987-10-23	0.03	1987-11-19
1987-07-09	0.04	1987-08-05
1987-06-22	0.03	1987-07-14
1987-02-23	0.03	1987-03-26
1985-09-23	0.02	1985-10-21
1985-06-17	0.02	1985-07-15
1984-01-27	0.02	1984-02-29
1982-08-16	0.40	1982-09-13
1982-08-10	0.06	1982-09-13

公司名稱	梯瓦制药
行業分類	制药
業務描述	Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

梯瓦製藥 TEVA 深 滬

32.01

個股概要

財務分析

公司資料

相關新聞

分紅派息

相關新聞

公司簡介

梯瓦製藥 TEVA 深滬